Results 31 to 40 of about 77,471 (339)

Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer.

Lung Cancer, 2023
OBJECTIVES The identification and targeting of actionable genomic alterations (AGA) have revolutionized the treatment of cancer in general and mostly for non-small cell lung cancer (NSCLC).
S. Daher, A. Zer, R. Tschernichovsky, R. Yacobi, I. Barshack, S. Tsabari, Y. Rottenberg, A. Zick, T. Gottfried, A. Lobachov, E. Marom, D. Urban, A. Saad, H. Gantz-Sorotsky, A. Onn, J. Bar   +15 more
semanticscholar   +1 more source

Oncogenic PIK3CA mutations increase dependency on the mRNA cap methyltransferase, RNMT, in breast cancer cells [PDF]

Open Biology, 2019
Basic mechanisms in gene expression are currently being investigated as targets in cancer therapeutics. One such fundamental process is the addition of the cap to pre-mRNA, which recruits mediators of mRNA processing and translation initiation ...
Sianadh Dunn, Olivia Lombardi, Radoslaw Lukoszek, Victoria H. Cowling   +3 more
doaj   +1 more source

Concurrent Detection of Circulating Tumor Cells and Circulating Tumor DNA in Triple-negative Breast Cancer

Asian Pacific Journal of Cancer Care, 2021
Objective: Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) provide tumor information in breast cancer. Our objective was to characterize CTCs, and contrasted them with ctDNA PIK3CA mutation in 24 triple-negative breast cancer (TNBC ...
Henry L Gomez, Carlos A. Castaneda, Miluska Castillo, James Reuben, Hui Gao, Nnacy Suarez, Luis A. Bernabe, Jose M. Cotrina, Jorge Dunstan, Marco Velarde, Julio Abugattas, Henry Guerra   +11 more
doaj   +1 more source

KRAS/NRAS Mutations Associated with Distant Metastasis and BRAF/PIK3CA Mutations Associated with Poor Tumor Differentiation in Colorectal Cancer

International Journal of General Medicine, 2023
Juanzi Zeng,1,2 Wenwei Fan,3 Jiaquan Li,1,2 Guowu Wu,1,2 Heming Wu2 1Department of Medical Oncology, Meizhou People’s Hospital, Meizhou Academy of Medical Sciences, Meizhou, People’s Republic of China; 2Center for Precision Medicine, Meizhou People’s ...
Zeng J, Fan W, Li J, Wu G, Wu H
doaj  

Inhibitors of cyclin-dependent kinases 4/6 for breast cancer patients with different somatic mutations of the PIK3CA gene

Медицинский совет, 2020
Introduction. Breast cancer is the leader in cancer incidence in theRussian Federation. The tumor is considered extremely heterogeneous and the luminal subtypes of breast tumors occupy a special place, since they are considered relatively favorable in ...
A. F. Nasretdinov, N. I. Sultanbaeva, Sh. I. Musin, O. N. Lipatov, A. A. Izmailov, R. T. Ayupov, K. V. Menshikov, A. V. Pushkarev, A. V. Sultanbaev   +8 more
doaj   +1 more source

Expression of PIK3CA, PTEN mRNA and PIK3CA [PDF]

, 2013
PURPOSE: High activity of the intracellular phosphatidylinositol-3 kinase (PI3K) pathway is common in breast cancer. Here, we explore differences in expression of important PI3K pathway regulators: the activator, phosphatidylinositol-3-kinase catalytic ...
Sorensen, Boe Sandahl, Wium-Andersen, Marie Kim, Nexo, Ebba, Marie Kim Wium-Andersen, Brügmann, Anja, Palimaru, Irina, Ebba Nexo, Irina Palimaru, Boe Sandahl Sorensen, Irina IrinaPalimaru, Anja Brügmann   +10 more
core   +2 more sources

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers

Genome Medicine, 2023
Background Mutations in the p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3K), encoded by the PIK3CA gene, cause dysregulation of the PI3K pathway in 35–40% of patients with HR+/HER2– breast cancer.
K. Hutchinson, Jessica W. Chen, H. Savage, T. Stout, F. Schimmoller, J. Cortés, S. Dent, N. Harbeck, W. Jacot, I. Krop, S. Trabucco, S. Sivakumar, E. Sokol, T. Wilson   +13 more
semanticscholar   +1 more source

Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis

Breast Cancer Research and Treatment, 2023
In light of the clinically meaningful results of the PI3K inhibitors in PIK3CA-mutated metastatic breast cancer (BC) patients, the reliable identification of PIK3CA mutations is of outmost importance.
Justus Rosin, Ella Svegrup, Antonios Valachis, I. Zerdes   +3 more
semanticscholar   +1 more source

Molekylære tester for deteksjon av PIK3CA mutasjoner blant menn og postmenopausale kvinner med HR+/HER2–, lokalavansert eller metastasert brystkreft: Metodevurdering [PDF]

, 2022
Key message The Norwegian Institute of Public Health was commissioned to evaluate molecular tests for the identification of somatic PIK3CA mutations in men and postmenopausal women with HR+/HER2–, advanced or metastatic breast cancer (BC).
Hamidi Ashtiani, Vida, Meneses Echavez, Jose Francisco, Bidonde Torre, Maria Julia, Flodgren, Gerd Monika   +3 more
core  

PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy

Scientific Reports, 2023
There is little data concerning the implications of PIK3CA mutations outside of the known hotspots described in ER+/HER2− metastatic breast cancer (mBC). Similarly, PIK3R1 mutations could also lead to activation of PI3K pathway, but are poorly described.
Z. Tharin, C. Richard, V. Derangère, A. Ilie, L. Arnould, F. Ghiringhelli, R. Boidot, S. Ladoire   +7 more
semanticscholar   +1 more source